Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
16
PRTA Quote, Financials, Valuation and Earnings
Last price:
$15.41
Seasonality move
:
10.81%
Day range:
$14.89 - $15.50
52-week range:
$11.70 - $41.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.21x
P/B ratio:
1.54x
Volume:
477.6K
Avg. volume:
637.3K
1-year change:
-60.96%
Market cap:
$824.9M
Revenue:
$91.4M
EPS (TTM):
-$2.48
Analysts' Opinion
-
Consensus RatingProthena Corp PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.75, Prothena Corp PLC has an estimated upside of 224.53% from its current price of $15.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $15.33.
Fair Value
-
According to the consensus of 7 analysts, Prothena Corp PLC has 224.53% upside to fair value with a price target of $49.75 per share.
PRTA vs. S&P 500
-
Over the past 5 trading days, Prothena Corp PLC has overperformed the S&P 500 by 19.5% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Prothena Corp PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Prothena Corp PLC revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Prothena Corp PLC reported revenues of $970K.
Earnings Growth
-
Prothena Corp PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Prothena Corp PLC reported earnings per share of -$1.10.
Enterprise value:
305.6M
EV / Invested capital:
0.57x
Price / LTM sales:
6.21x
EV / EBIT:
--
EV / Revenue:
2.29x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-1.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-19.93%
Net Income Margin (TTM):
-98.86%
Return On Equity:
-23.56%
Return On Invested Capital:
-23.56%
Operating Margin:
-6857.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5.2M | $141M | $133.4M | $84.9M | $970K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$164.6M | -$112.6M | -$168.2M | $10.3M | -$66.5M | |
| EBITDA | -$159.6M | -$111.9M | -$167.2M | $10.5M | -$66.3M | |
| Diluted EPS | -$3.34 | -$1.42 | -$2.48 | $0.38 | -$1.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $320.5M | $607.5M | $524.6M | $690.6M | $535M | |
| Total Assets | $355.8M | $632.7M | $554.4M | $746.9M | $595.3M | |
| Current Liabilities | $21.7M | $29.2M | $50.6M | $53.4M | $46.4M | |
| Total Liabilities | $146.3M | $142.2M | $149.8M | $129.7M | $60.9M | |
| Total Equity | $209.5M | $490.5M | $404.6M | $617.2M | $534.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$126.3M | -$87.8M | -$153.3M | $9.5M | -$45.2M | |
| Cash From Investing | -$632K | -$1.4M | -$1.8M | -$442K | -$9K | |
| Cash From Financing | $22.5M | $265.4M | $2.1M | $2.7M | $333K | |
| Free Cash Flow | -$126.9M | -$89.3M | -$155.1M | $9.1M | -$45.2M | |
PRTA
Sector
Market Cap
$824.9M
$45.6M
Price % of 52-Week High
36.9%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
0.04%
-0.74%
1-Year Price Total Return
-60.96%
-31.35%
Beta (5-Year)
0.086
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$13.97
200-day SMA
Sell
Level
$20.26
Bollinger Bands (100)
Sell
Level
15.11 - 20.81
Chaikin Money Flow
Sell
Level
-4.3M
20-day SMA
Buy
Level
$14.44
Relative Strength Index (RSI14)
Buy
Level
52.45
ADX Line
Buy
Level
18.99
Williams %R
Neutral
Level
-39.094
50-day SMA
Sell
Level
$15.68
MACD (12, 26)
Sell
Level
-0.36
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
19.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9284)
Buy
CA Score
(Annual)
Level (-0.1606)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (0.3204)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Stock Forecast FAQ
In the current month, PRTA has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PRTA average analyst price target in the past 3 months is $49.75.
-
Where Will Prothena Corp PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Prothena Corp PLC share price will rise to $49.75 per share over the next 12 months.
-
What Do Analysts Say About Prothena Corp PLC?
Analysts are divided on their view about Prothena Corp PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prothena Corp PLC is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Prothena Corp PLC's Price Target?
The price target for Prothena Corp PLC over the next 1-year time period is forecast to be $49.75 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is PRTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Prothena Corp PLC is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRTA?
You can purchase shares of Prothena Corp PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prothena Corp PLC shares.
-
What Is The Prothena Corp PLC Share Price Today?
Prothena Corp PLC was last trading at $15.41 per share. This represents the most recent stock quote for Prothena Corp PLC. Yesterday, Prothena Corp PLC closed at $15.33 per share.
-
How To Buy Prothena Corp PLC Stock Online?
In order to purchase Prothena Corp PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
